November 22, 2021 at 4:15 PM EST
ROCKVILLE, Md.–(BUSINESS WIRE)–Nov. 22, 2021– GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that Lisa DeLuca, Ph.D., has joined its executive leadership team as Vice President, Regulatory Affairs. Dr. DeLuca is a veteran regulatory expert who has previously led the strategy-formation and execution of multiple global NDA submissions and product registrations. Most recently she was the head of regulatory affairs at Nuvation Bio and a member of its executive leadership team.
“Lisa is a seasoned executive who brings to GlycoMimetics significant expertise in regulatory strategy and agency interactions. She has successfully led programs requiring interface with both the FDA and international authorities. Most notably, while at Celator Pharmaceuticals, she directed regulatory activities surrounding the submission of an NDA for Vyxeos, which led to its approval for the treatment of newly diagnosed acute myeloid leukemia patients. Her decision to join GlycoMimetics as head of our regulatory affairs group represents an important step forward as we prepare to engage more definitively with the FDA with respect to the potential successful outcomes of the two ongoing registrational trials of uproleselan in AML. Her expertise in oncology and hematology constitutes a unique fit with both our late-stage uproleselan program and the Company’s pipeline opportunities,” commented Harout Semerjian, GlycoMimetics’ Chief Executive Officer. Read More